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H

umans began cultivating plants
roughly 10,000 years ago when
the estimated global population was
less than 10 million (24). Early farmers
had to learn which plants could be cultivated and how plants could be improved through breeding by trial and
error (7). Evidence suggests that progenitors of modern varieties of wheat
and barley were first domesticated
nearly 10,000 years ago in the Middle
East. Soybeans were domesticated approximately 5,000 years ago and rice
approximately 6,000 years ago in Asia.
Early varieties of maize were grown in
Central America nearly 9,000 years ago
(12). Although varieties of these common crops are genetically diverse, major changes in the genetics of domesticated crops have been sporadic (e.g.,
soybean) (14). Modern common bread
wheat is a hexaploid (6n) species that
has three times as many chromosomes
and genes as its probable wild progenitor, while pasta wheat (durum) is
tetraploid (4n). Hexaploid wheat varieties were derived from naturally hybridized grass family relatives represented by diploid (2n) and tetraploid
(4n) species (8).
Most of the genetic diversity that
has improved agricultural production
throughout the history of farming was
developed through natural mutations
and selective breeding. However, since
the early 1900s plant scientists have
used chemical and radiation mutagenesis to increase genetic diversity (18). We
know that the majority of mutations are
harmful, and plant breeders work hard
to select only those that are beneficial.
This process has helped feed a growing human population, which is estimated to have been 300 million 2,000
years ago and is now more than 7 billion. However, methods used in the past
to improve agricultural production are
unlikely to keep pace with the current
growth rate of the human population.

Growing Challenges for Food
Production
Norman Borlaug won the Nobel Peace prize in 1970 for his efforts
that led to the “green revolution:’ In a
speech reviewing 60 years of agricultural improvements (Table I), he credited improved plant genetics, increased
use of irrigation, increased and efficient
use of fertilizers, and increased mechanization as the major factors leading
to the tripling of production of wheat
and rice in Asia between 1960 and 2000
(1). Historically, genetic changes have
been achieved by introducing unknown
changes in genes through crossbreeding
with wild relatives, development of hybrid varieties, and mutations induced by
chemicals or radiation followed by careful breeding for selection. Borlaug noted
that more precise genetic modification (GM) technology will be needed to
maintain a sufficient food supply to feed
the growing human population, which
is expected to reach 10 billion by 2050.
Today, agricultural and food supply systems around the world are being
challenged by political and economic
barriers that are slowing or blocking the
introduction of commonly consumed
varieties of plants and animals that
have been improved by highly specific
GM. This is occurring at a time when the
world population continues to grow,
per capita consumption of resources
is growing even faster, and prime agricultural land is being converted to urban or industrial uses. In addition, growing concerns about the environmental
risks associated with the use of chemical
pesticides, herbicides, and fertilizers are
pushing farmers to reduce inputs that
have helped raise productivity over the
past 100 years. Fewer people are willing
or able to work as farmers, and meeting growing demands requires continued improvements in the efficiency of
food production. Rising food costs associated with crop production on marginal

farmland, crop failures due to changing
weather patterns, high transportation
costs, and energy use could be partly
mitigated by the improvements in agricultural efficiencies offered by some
GM crops. While there is a growing demand for and supply of organic foods,
it is not clear that organic methods can
meet current and future demands and
supplant industrial agriculture, which
has become the dominant production
method. In addition, some GM varieties have been demonstrated to reduce
the need for applied chemical pesticides and, thus, are environmentally
beneficial.
As the human population continues to grow, we are not only increasingly converting farmland to urban uses,
more people are eating meat, which is
not energetically efficient. To compensate, we need to increase the rate of
crop improvements, and as argued by
Norman Borlaug, we need to use all
available genetic tools, in cluding bio-
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technology (genetic engineering), and
improve use of chemical fertilizers, water, and mechanization to meet growing demands.
Importance of Genetic Complexity
and Diversity of Non-GM Plants
Genetic diversity is essential to allow efficient growth of crops under diverse environmental conditions (e.g.,
day length, temperature, moisture
level, soil type, pests, and disease conditions). Significant increases in yield
have been achieved by combining different genetic types in parent lines and
even more through hybrid generation
from 1930, when the average corn production in the United States was 30 bu/
acre, to 2004, when the average was
150 bu/acre (25). Hybrids of corn are
produced by crossing genetically diverse parents to produce high-yielding seeds that generally outperform inbred line yields. Although hybrid seeds
cost more, the increased yield usually
pays farmers a dividend. Recent work
also has demonstrated that inbred parental lines have substantial genetic diversity (33).
While great improvements have
been made possible by advanced molecular breeding and selection, the introduction of genes from other species has opened up the possibility of
developing plants that could never be
achieved through breeding alone (e.g.,
resistance to the European corn borer
and corn rootworm by the introduction of genes from the bacterium Bacillus thuringiensis). The safety of bacterial pesticides has been studied, and
they are regulated by the U.S. Environmental Protection Agency (EPA)—the
same agency that now regulates insectresistant GM crops (23). The methods
of using plant breeding, genetic engineering, and organic farming should be
complementary, and the safety assessment of biopesticides should be similar because the active ingredients are
the same.
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Introducing New Traits Through
Biotechnology
Watson and Crick won the Nobel
Prize in 1963 for describing the basic
structure of DNA polymers in 1953 (37).
DNA is made up of unique extended
sequence arrangements of four simple
nucleotides (ATGC). They suggested a
model structure of amino acids defined
by a triple nucleotide codon arrangement, which with the anti-parallel DNA
strands allowed accurate replication of
the chromosomes. Of course, more details were later identified by other scientists (36). Understanding the structure of
DNA was essential to enable biotechnology, and work by other scientists
was necessary to develop many of the
molecular tools used in the 1960s and
early 1970s that led to the production of
the first specifically genetically modified
plants in the 1970s.
Contribution of GM Plants to the
Food and Fiber Supply
Scientists around the world have
been developing potentially useful GM
crops since the early 1990s. Many of
these GMOs will never be used commercially because they will fail to function, will not meet regulatory health
or environmental safety criteria, or the
value of the crop would not meet the
costs of development and regulatory
studies. However, some could be successful. The area of land cultivated in
GM crops in 2012 surpassed 160 million
hectares (17). Almost all of the approved
GM plants have been invented or the
rights purchased by large corporations
with sufficient infrastructure and capital
to complete registrations. Information
about specific plants, crops, and approvals is available from the Center for
Environmental Risk Assessment (CERA)
(3) and the International Service for the
Acquisition of Agri-biotech Applications
(16). CERA lists 109 GMOs approved for
food or feed in the United States, including alfalfa, canola, chicory, cotton,
flax, linseed, maize, papaya, plum, po-

tato, sugar beet, tomato, and wheat. A
number of these GMOs are not currently
commercially available (e.g., GM wheat).
In the United States, 88% of corn,
94% of cotton, and 93% of soybeans
grown are GM varieties (35). The dominant GM traits are herbicide tolerance
and insect resistance. Genes for the primary insect resistance traits have come
from a bacterium (B. thuringiensis) that
farmers have used as an organic pesticide since the 1940s (31). Insect-resistant plants reduce the need for chemical insecticides. A few viral resistance
traits have been introduced that have
reduced crop losses due to plant pathogens such as Papaya ringspot virus, Potato leafroll virus, and Potato yellows virus (3). However, a number of GMOs
that were approved in the United States
between 1995 and 2013 have not been
approved for growing or importation in
many parts of the European Union and
some other countries, even though they
were tested prior to commercial release
and found to be as safe as conventionally produced varieties using evaluations
recommended by the Codex Alimentarius Commission guidelines (4).
New GM developments include nutritionally enhanced commodity crops
that can provide essential vitamins or
precursors (e.g., rice and maize with
high 13-carotene contents), as well as
minerals (e.g., rice with high iron content), at lower costs compared with alternative food supplements. The Gates
Foundation (www.gatesfoundation.org),
the US. Agency for International Development (USAID), HarvestPlus, and
other organizations are working to increase food security and nutrient availability using a variety of techniques to
improve food crops, including genetic
modification.
General Food Safety
The US. Food and Drug Administration (FDA) recognizes that all foods
have inherent risks for some individuals. For example, individuals with diabe-

Table 1. Factors in the “green revolution” from 1961 to 2000*

Year
1961**
1970
1980
1990
2000

Adoption of Modern Varieties 				
(million ha (% total growing area))
Irrigation Area
Fertilizer Use
Tractors
Wheat
Rice
(million ha)
(million tons)
(million)
0(0)
14 (20)
39 (49)
60 (70)
70 (84)

0(0)
15 (20)
55 (43)
85 (65)
100 (74)

87
106
129
158
175

2
10
29
54
70

0.2
0.5
2.0
3.4
4.8

Total Cereal
production
(million tons)
309
463
618
858
962

* Adapted from Borlaug (1).
** Source: FAOSTAT (July 2002) and Borlaug’s estimaled adoption (1) based on International Maize and Wheat Improvement Center (CIMMYT) and International Rice Research Institute (IRRI) data.
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tes must restrict their sugar intake. Individuals with insufficient lactase enzyme
experience diarrhea and bloating if they
consume products that contain lactose
(i.e., dairy products). Individuals with celiac disease (1-2% of the global population) must avoid gluten proteins from
wheat, barley, and rye to prevent ongoing damage to their upper small intestine and potentially more serious autoimmunity, malnutrition, and/or cancer. A
few individuals with IgE-mediated food
allergies must avoid the foods that trigger their disease or risk experiencing severe anaphylaxis and potentially death.
Other consumers with food allergies experience less severe symptoms. Many
legume species must be cooked to inactivate lectins, protease, or amylase inhibitors and prevent malabsorption or
pain and diarrhea. The FDA has required
food labels for ingredients and nutrients for many years. However, passage
of the Food Allergy Labeling and Consumer Protection Act (FALCPA) by the
U.S. Congress in 2006 created additional
regulations for labeling of allergens and
celiac-eliciting food ingredients.
FDA Regulation of GM Plants
The FDA published a policy statement concerning the safety assessment of foods derived from GM crops
(organisms) in 1992 (6), stating that recombinant DNA plants would be regulated within the existing Federal Food,
Drug and Cosmetic Act. As stated, a GM
plant having similar components (proteins, fats, oils, and carbohydrates) as
a non-GM counterpart and no apparent risk from the inserted gene and expressed new protein is treated as a normal constituent and does not require
special labeling. However, if there is any
indication of a new risk, the novel ingredient must be treated as a food additive. The 1992 FDA policy (6) provided
the EPA with lead-agency responsibility
for GMOs with pesticidal proteins and
the U.S. Department of Agriculture leadagency responsibility in the case of GM
meat or poultry. The policy clearly states
that these agencies will work in a cooperative manner, with the FDA having ultimate authority on food safety. The primary focus of the policy guidelines is to
determine whether a new protein presents a new potential risk of allergenicity
or toxicity. In addition, the safety characteristics of the gene donor organism and
the host organism (gene recipient) must
be considered with regard to potential
characteristics related to food safety.
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Before gaining regulatory approval,
developers of GMOs must supply study
data verifying that their GMO products
are safe. Based on the safety record and
benefits provided by their approved
GMO products, biotech companies are
seeing GM seed sales rise, and the technology has gained wide acceptance by
farmers. Of course, any agricultural practice has an impact on the environment,
but in general GMOs are no more hazardous than their non-GM counterparts.
Evaluation and Regulation Based on
Food Safety Principles
Before any GM plants were approved
and released commercially in 1996, scientists from diverse disciplines were discussing opportunities, risks, and appropriate controls for the technology (2,13).
The International Food Biotechnology
Council (IFBC) was formed in 1988 and
brought together “150 representatives of
government agencies from 13 countries,
industrial scientific organizations, professional societies, congressional-legislative
staffs, public interest-consumer groups
and academicians” from the food and
biotechnology industries to draft a food
safety document covering the general
topic of the safety of foods derived from
biotechnology (22). The full recommendations were published in a supplement
to volume 12 of Regulatory Toxicology
and Pharmacology (15). The consensus
was that GM crops should be regulated
within the legal and regulatory framework of foods and food additives that
was developed over more than 80 years.
The IFBC agreed that the primary task
is to characterize the potential risk of a
new protein or trait and to ensure that
foods derived from the GMO are substantially equivalent to non-GM counterparts, at least within the range of commonly used nonGM varieties of the same
species. The assessment strategy was refined further in scientific consultations,
culminating with a Codex Alimentarius
guideline published in 2003 and republished in 2009 (4).
This 2003 Codex document laid the
foundation for regulation of GM products in the United States, Canada, Japan,
and the international treaty members
of the Codex Alimentarius Commission
and was updated with minor revisions in
2009 (4). The guidelines recognize that
all foods pose some risks for some individuals. The 4-6% of individuals worldwide with food allergies must avoid the
specific foods that cause their reactions,
while those without allergies can safely

consume the same food (30). By the same
token, individuals with celiac disease (12% of the world population) must avoid
gluten proteins from wheat, barley, and
rye (19,29). The primary concern for food
developers is to avoid transferring a major allergen or potentially cross-reactive
protein into a new food source.
Understanding the Technical
Changes Introduced through
Biotechnology
Although basic science courses provide knowledge on the structure of genetic material, reproduction, synthesis of proteins, and general physiology,
many consumers do not understand the
basic science behind biotechnology or
that the products of genetic modification are predictable based on the nucleotide and protein sequences of the
new trait. At the same time, the scientists who develop GMOs and the regulators who evaluate their safety must
understand the subject in sufficient detail to ensure the proper functioning of
a GMO and to understand the fidelity
and nonrandom nature of living organisms. To bridge this gap, we as scientists
must learn to communicate to consumers the concepts, reliability, and adequacy of the safety assessments used
to ensure that GMOs are safe.
It is difficult for consumers to find
simply stated information that describes
the extensive premarket testing required
for GMO products. Social and commercial news media sources frequently present polarized positions regarding the
benefits, safety, and dangers of GMOs,
often portraying reports of adverse effects as truthful and failing to mention
the extensive literature and evidence
supporting GMO safety.
It is important that consumers understand that unless they are intended
to be different from their non-GM counterparts (e.g., as Golden Rice differs
from regular rice) GMOs are the same
in terms of their food safety and nutritional properties. As a result, the basic
principles of food safety and food safety
evaluation used for nonGM foods are
fully capable of detecting any hazards
associated with GM foods.
Characterizing the GMO DNA Insert
and Function
The GMO developer must demonstrate appropriate function of the inserted gene, expression of the protein,
and appropriate function of the specific
new GMO. The DNA may be inserted
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in many different regions of the host
DNA, as long as it functions appropriately and does not disrupt other essential functions. Sometimes multiple copies are inserted into the chromosomes
or insertion may occur at more than one
location. Construction of the transformation vector and gene cassette must
be defined and the method of insertion specified. The flanking sequence
at the point of insertion is characterized to identify any unexpected or fusion proteins that might be expressed in
the GMO that were not expressed in the
non-GM host. Newer vectors and methods of controlling insertion are being
developed and used, but it is important
to realize that many processes are patented, and the techniques used in the
1990s are still scientifically acceptable
for new products developed in 2014.
Thus, if an independent scientist develops a new GM using older technology,
it should be allowed if the product is
proven safe and effective.
Characterizing the New Proteins
Consideration of potential risks is
focused primarily on the safety of the
new protein. The evaluation process
begins by considering the possible history of safe (or unsafe) human exposure to the gene source. Extra testing
may be required for genes taken from
sources that are commonly allergenic
or toxic, depending on whether there is
information regarding the safety of the
specific protein encoded by the gene.
The amino acid sequence as expressed
in the GMO must be verified, and the
structure and function of the newly expressed protein are evaluated as well.
Evaluating Potential Allergenicity of
GMOs
Few foods cause severe allergic reactions, and very few proteins within
those foods are responsible for sensitization and elicitation. For example, there
are four major allergenic proteins found
in peanuts, and these proteins are abundant. Peanut allergy is thought to cause
~50–80 deaths per year in the United
States in consumers who are allergic and
unsuccessful in avoiding peanuts in the
foods they consume. Soybean, which is
estimated to cause less than one fatal
allergic reaction per year in the United
States, contains eight or nine moderately
allergenic proteins in its seeds.
It is important to prevent the transfer
of an allergenic protein from food airway, contact, or injection sources into
a new food that an allergic consumer

would not recognize as containing the
allergen. For instance, transferring the
allergenic 2S albumin Ara h 2 from peanut into rice would put many people
who are allergic to peanut at risk of severe reactions. It is relatively easy, however, to identify most of the important
risks of transferring food allergens if a
few simple steps are followed. This was
demonstrated in 1996 (26) by the evaluation of the protein from a Brazil nut
gene that was transferred into soybean
to increase its nutritional properties
for agricultural animals—a case where
substantial risk was possible. The tests
were performed because the source
of the gene is known to cause allergic
reactions in some individuals. Today,
more allergens have been identified and
added to databases such as AllergenOnline, and a similar protein would have
been flagged as a likely allergen requiring serum IgE testing due to high sequence identity matches to other allergenic 2S albumins (described below).
The steps required for the assessment of GM crop allergenicity have often been misinterpreted, or the risks
have been overemphasized (11). Undoubtedly the most important step is
a bioinformatics search to compare the
sequence to those of known allergens
using a well-characterized allergen database (10). AllergenOnline (also termed
the FARRP database by some; http://
www.AllergenOnline.org ) currently
is the only peer-reviewed, sequence
searchable database available for public use. It is updated annually, and version 14 (released January 2014) includes
1,706 sequences in 645 taxonomic
groups. The sequences are selected
based on criteria to evaluate data published to demonstrate IgE binding, using clinically defined serum donors and
test method criteria. Sequences in the
NCBI Protein database — http://www.
ncbi.nlm.nih.gov/guide/proteins — may
also be used for comparison using key
word limits (e.g., allerg*, allergen, or allergenicity), but the user is then responsible for evaluating the relevance of any
match: there are more than 52,000 sequences in the database that are associated with the key word “allergen” (as
of April 26, 2014), and for many, there
is no proof of IgE binding or causing reactions. The most informative search is
a full-length alignment, and if the new
GM protein matches a known allergen
with >50% identity and a very small E
score, the alignment is likely to show
cross-reactive IgE binding and possibly shared allergic elicitation. How-
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ever, allergens are not equal in potency
or frequency of elicitation. In addition,
the Codex guidelines (4) recommend
searching for matches of >35% identity
over any alignment of 80 or more amino
acids using either the FASTA or BLASTP
programs (4). In addition, many countries expect a short identity match comparison that looks for segments of eight
contiguous amino acids that match any
allergen. However, there are a number
of publications that demonstrate a short
segment match is not predictive (32).
If the GM protein aligns with an allergen at >35% identity over 80 or
more amino acids, serum IgE binding
tests would normally be required, using
sera from donors that are clinically defined with the appropriate allergies and
validated methods (9,11). Some proteins identified in AllergenOnline or in
other publications rarely cause any allergic reaction. It will prove impossible
to find qualified donors for such proteins, but for them the risk of allergic
reaction to the GM protein is likely to
be extremely low. Additional considerations include the need to use sera from
subjects with other allergies as negative control donors to ensure that IgE
binding is specific and also to use positive and negative control antigens (9).
If binding is observed, it is usually informative to perform specific inhibition
tests to validate the specificity of binding. If the GMO developer wants to proceed with a product that has some positive binding, it is necessary to evaluate
the biological relevance of the binding
using basophil activation or histamine
release. Alternatively, in vivo skin prick
tests or other challenges would be appropriate, although it is essential to consider whether the potential risk to the
patients is warranted (11).
Additional steps in the Codex guidelines (4) are more relevant for determining whether a new protein might become
an allergen based on the characteristics
of many known food allergens. Or alternatively, they may be used in considering appropriate risk assessment and mitigation steps if the protein is determined
to be an allergen after approval. The stability of the protein in pepsin and under heating conditions may be useful in
the initial evaluation because many major food allergens are relatively abundant and stable in pepsin at pH 2. Stability in heat means the protein maintains
its three-dimensional form and function
when cooked at “normal” cooking temperatures. Many major food allergens are
also quite abundant in a food. Therefore,
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pepsin and heat-stable, abundant proteins may pose a risk of sensitization in
the future, although there are a number
of very stable and abundant proteins that
do not cause food allergies. It would be
extremely useful to have a predictive animal model or cell culture system (e.g.,
dendritic cells, T cells, and B cells) for accurate evaluation of the sensitizing potential of novel proteins. However, no animal model, cell culture method, complex
protease digestion protocol, or computer
prediction modeling has yet been demonstrated to accurately predict the risk of
sensitization for humans (20,21).
Evaluating Potential Toxicity of
GMOs
The Codex guidelines call for evaluation of the potential toxicity of a protein (4). In their review, Delaney et al. (5)
provide an interesting model for safety
evaluation for potential toxicity. It is
based on the source of the gene (i.e.,
whether it is likely to be toxic or not)
and a bioinformatics match to known
toxic proteins or enzymes that make
toxic metabolites. A history of safe use
or human exposure is a key component of a toxicity evaluation. There are
very few proteins that are toxic when
ingested, such as botulinum and ricin, which are highly toxic. Even proteins with fairly high identity matches
to these proteins are not known to
be toxic (unpublished data). There are
many “toxic” proteins from stinging insects, snakes, and other organisms, but
many of them are unlikely to cause toxicity if consumed at low concentrations.
A comparison of the GM protein by
BLASTP to the NCBI protein database using key word limits “toxic” or “toxin” will
identify significant matches to toxic proteins. There are no absolute criteria for
this search, so it is important to use relative comparisons if a significant match
is found (e.g., >50% identity over most
of the length of the protein, with an E
score smaller than 1e-15). In this case a
BLASTP search using the GM protein with
no key word might identify proteins with
a history of safe use and high identity
to the GM protein. A search comparing
the matched toxin to other proteins in
the NCBI database also would be instructive. If the gene is from a toxic sequence
source and matches a toxin with modest identity, then specific tests should be
performed based on the toxic characteristics of the protein (e.g., neurotoxin for
many snake and spider venoms or liver
toxicity for some mycotoxins). Some

R. E. Goodman in Cereal Foods World 59 (2014)
countries require an acute mouse gavage
with the protein if the GM protein is insecticidal (e.g., EPA) through oral administration at high dose followed by observation of clinical signs for 14 days before
sampling for blood chemistry. The mice
are then killed, and their organs are analyzed for differences in weight compared
with control mice and for gross pathology and, when appropriate, histopathology following good laboratory practices.
Some governments require a 90 day,
rat whole-feeding study for most GM
crop products. In this case, groups of
rats are fed diets with a high inclusion
rate of the GM crop material and identical doses of non-GM crop material from
genetically similar varieties. Additional
commercial non-GM varieties are used
with groups of rats to evaluate minor statistical differences that might be due to
chance. This is not a true toxicity study,
but a nutritional equivalence study.
There is no need to perform chronic
studies or multigeneration studies unless there is a scientifically justified rationale to suggest the GM product or
protein is likely to have long-term effects. In my opinion, the currently approved GM products (109 in the United
States) do not have characteristics that
would warrant such tests. In any test
that is intended to identify potential
toxicity, there must either be a history
that the test can predict a toxic effect in
humans or an animal species of concern,
or positive and negative control test articles must be included in the study to
evaluate the biological relevance of any
noted difference(s).
Analysis of Nutritional Adequacy
Specific foods are consumed to supply nutrients. Humans are omnivores
and can develop and survive on highly
varied diets. However, we generally are
concerned with feeding nutritionally adequate diets to agricultural species (e.g.,
chickens, cows, fish, and pigs) that have
restricted diets. Therefore, it is important to ensure that the nutritional properties of a GMO are similar to those of
non-GM varieties intended for similar
use. In most cases, simple proximate
analysis is all that is necessary, using
samples from multiple field trial sites.
However, for specific crops there may
be specific nutrients (e.g., vitamins, minerals, and fatty acids) or antinutrients
(e.g., phytate, lectins, amylase, or protease inhibitors) that are monitored to
verify “safety.” If the new GM protein is
an enzyme that is active in the plant, it

is important to evaluate specific metabolites based on the functional properties
of the enzyme and the metabolic pathways in the host (gene recipient). For example, Monsanto evaluated the impact
of inserting the enzyme CP4 EPSPS in
its Roundup Ready soybean because the
enzyme is known to produce metabolites that lead to the formation of aromatic amino acids, flavonoids, and other
aromatic amino acids or isoflavones. No
significant differences were found between non-GM and herbicide-tolerant Roundup Ready soybeans (27,34).
Some future GM crops are intended to
have changes in their nutrient profIles.
For example, Golden Rice 2 (GR2) expresses high levels of β-carotene due to
the insertion of two genes that express
enzymes essential for the synthesis of
β-carotene (28). Non-GM rice does not
normally express β-carotene (also called
provitamin A). To make a health claim
that GR2 has the potential to provide
sufficient provitamin A, the developers
had to demonstrate a substantial accumulation of the compound and associated α-carotene in the rice grain (28).
Conclusions
To date, there is no proof of harm
to humans or farm animals from consumption of approved GM varieties of
plants. To maximize efficiency and minimize costs, the safety evaluation process
for food and feed should be the same in
all countries. It is unfortunate that there
isn’t a mechanism for global approval
because the current system leads to
long delays in global trade of commodities and finished food products. The
process also adds costs when reports
and, in some cases, duplicate studies are
performed. It is also clear that generically labeling foods as “GMO” will not
provide any relevant health benefit, because any possible harm will be product
specific, and the dose and, thus, exposure will vary markedly between products. Labeling only provides a way to
discriminate against a technology with
many important benefits. To combat unsubstantiated concerns, it is clear that
scientists need to develop more effective methods of communicating with
the public to provide assurances about
the safety of foods produced from approved GM varieties.
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